Virtual Meetings 2023

Meet The Professor: Optimizing the Management of Ovarian Cancer

For an up-to-date schedule of upcoming sessions in this series, please click here.


Antonio González-Martín, MD, PhD
Director, Medical Oncology Department
Cancer Center Director
Clínica Universidad de Navarra
Madrid, Spain

Bradley J Monk, MD
Division of Gynecologic Oncology
University of Arizona College of Medicine
Creighton University School of Medicine
Phoenix, Arizona

Kathleen N Moore, MD, MS
Associate Director, Clinical Research
Virginia Kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase I Drug Unit
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the University of Oklahoma HSC
Associate Director, GOG Partners
Board of Directors, GOG Foundation
Oklahoma City, Oklahoma

David M O'Malley, MD
Division Director, Gynecologic Oncology
The Ohio State University and The James Cancer Center
Columbus, Ohio

Neil Love, MD
Research To Practice

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, and Novocure Inc.


Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for ovarian cancer. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

Topics to Be Discussed

  • Up-Front Treatment of Advanced Ovarian Cancer (OC)
  • Emerging Novel Approaches to Up-Front Treatment of OC
  • Selection and Sequencing of Therapy for Patients with Relapsed/Refractory OC
  • Novel Investigational Approaches for OC

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer.

Learning Objectives

  • Consider available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and appropriately counsel patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adopted indications for FDA-endorsed PARP inhibitors for recurrent OC in order to optimally incorporate these agents into management algorithms.
  • Evaluate the biological rationale for and published clinical research data with the use of PARP inhibitors in combination with other systemic therapies, and consider the current and potential clinical and research implications of these findings for OC management.
  • Recognize the rationale for targeting folate receptor alpha in OC, determine optimal testing methods and assess the current role of novel approaches to therapeutically exploit this newly relevant biomarker.
  • Use published research data and evidence-based guidelines to inform the selection and sequencing of therapy for patients with platinum-sensitive or platinum-resistant recurrent OC. 
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and appropriately counsel patients about availability and participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr González-Martín Advisory Committee: Alkermes, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Daiichi Sankyo Inc, GSK, ImmunoGen Inc, Incyte Corporation, Kartos Therapeutics, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Sutro Biopharma, Tubulis; Contracted Research: GSK, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GSK, ImmunoGen Inc, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, PharmaMar. Dr Monk Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Myriad Genetic Laboratories Inc, Novocure Inc, Seagen Inc, Tesaro, A GSK Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Myriad Genetic Laboratories Inc, Tesaro, A GSK Company. Dr Moore Advisory Committee: Aadi Bioscience, Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, InxMed, Iovance Biotherapeutics, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, PTC Therapeutics, Regeneron Pharmaceuticals Inc, Verastem Inc; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, Duality Biologics, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, GSK, Lilly, Merck, PTC Therapeutics, Verastem Inc. Dr O'Malley Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, Adaptimmune, Agenus Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Duality Biologics, Eisai Inc, Elevar Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Genelux Corporation, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Imvax Inc, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, R-Pharm, Regeneron Pharmaceuticals Inc, Replimune, Roche Diagnostics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Clovis Oncology, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Nonrelevant Financial Relationship: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG, SWOG. 

SURVEY PARTICIPANT — Lainie Martin, MD — Advisory Committee: Elucida Oncology Inc, ImmunoGen Inc, Myriad Genetic Laboratories Inc, Sutro Biopharma; Contracted Research (to Institution): Agenus Inc, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc, Sutro Biopharma, Xencor.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, and Novocure Inc.